Study Suggests Ketamine Therapy , Could Help Treat Anxiety & Depression.<br />According to recent study, ketamine infusion <br />therapy was linked to a reduction in self-reported<br />symptoms of anxiety, depression and suicidal thoughts.<br />According to recent study, ketamine infusion <br />therapy was linked to a reduction in self-reported<br />symptoms of anxiety, depression and suicidal thoughts.<br />PsyPost reports that the study provides insight into the <br />effectiveness of ketamine therapy and evidence that <br />it could result in lasting and significant improvements.<br />The study was published in the <br />'Journal of Affective Disorders.' .<br />I am interested in this topic because <br />as ketamine intravenous therapy has <br />not been FDA approved for depression, <br />there have been few randomized <br />controlled trials to assess the efficacy <br />and safety of this treatment, Alison McInnes, the Vice President of <br />Scientific Affairs at Osmind, via PsyPost.<br />Therefore, it is essential that we <br />generate real-world evidence from <br />patients treated with ketamine <br />intravenous therapy in community settings <br />to convince insurers that the treatment <br />is effective and should be covered, Alison McInnes, the Vice President of <br />Scientific Affairs at Osmind, via PsyPost.<br />According to the team's results, <br />a significant number of patients <br />responded to the treatment. .<br />Over 49% of patients responded for <br />depression, while another 47.5% of <br />participants responded for anxiety.<br />PsyPost reports that the reduction <br />in symptoms was significant<br />both statistically and clinically. .<br />The results of the study found that intravenous ketamine <br />treatments had a greater impact on depression <br />than standard antidepressant monotherapy.<br />Ketamine intravenous therapy has <br />a robust effect size for treatment <br />resistant depression and for anxiety, Alison McInnes, the Vice President of <br />Scientific Affairs at Osmind, via PsyPost
